Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia [0.03%]
炎症性肠病相关结直肠肿瘤的统计与流行病学研究
Takahide Shinagawa,Satoshi Okada,Hiroshi Shiratori et al.
Takahide Shinagawa et al.
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are associated with an increased risk of intestinal neoplasia, representing a major long-term complication of chronic inflammation. This review s...
Nationwide trends in mediastinal tumor and myasthenia gravis surgery in Japan: a decade claims-based analysis (2014-2023) [0.03%]
日本全国纵膈肿瘤和重症肌无力手术十年趋势分析（2014-2023）
Masamitsu Kido,Satoru Okada,Tatsuo Furuya et al.
Masamitsu Kido et al.
Background: Mediastinal tumor surgery and extended thymectomy for myasthenia gravis (MG) have undergone significant changes with the advancement of minimally invasive techniques. However, nationwide population-based data ...
Breast cancer burden among women of reproductive age in China, Japan, and South Korea, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021 [0.03%]
中国、日本和韩国1990至2021年育龄女性乳腺癌疾病负担：全球疾病负担研究2021系统分析结果
Zhiyuan Rong
Zhiyuan Rong
Background: Breast cancer is the most common cancer among women globally, with incidence rates rising annually. However, systematic comparative studies on the burden of breast cancer among women of reproductive age in Eas...
Comparative efficacy of immune checkpoint inhibitor-based regimens versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma stratified by etiology: a systematic review and meta-analysis [0.03%]
基于免疫检查点抑制剂与酪氨酸激酶抑制剂治疗肝细胞癌的系统综述和meta分析：按病因进行分层的效力比较
Tzu-Rong Peng,Yun-Hui Huang,Ta-Wei Wu et al.
Tzu-Rong Peng et al.
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with limited treatment success in advanced stages. Tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvati...
Local treatment for metastatic and primary sites in metastatic renal cell carcinoma in the combination immunotherapy era: a narrative review [0.03%]
免疫治疗时代的转移性肾细胞癌的局部治疗：综述文章
Junya Abe,Takaya Murashima,Shimpei Kojima et al.
Junya Abe et al.
Advances in immuno-oncology (IO)-based systemic therapies have improved treatment outcomes for patients with metastatic renal cell carcinoma (mRCC). However, long-term survival of these patients remains challenging, highlighting the need to...
Online peer support for breast cancer survivors: protocol for a decentralized multicenter open-label pilot randomized controlled trial (HOPE-BC study) [0.03%]
乳腺癌幸存者在线同伴支持研究：一项分散式多中心开放性试点随机对照试验（HOPE-BC研究）方案
Ken Kurisu,Yosuke Uchitomi,Naomi Sakurai et al.
Ken Kurisu et al.
Background: The effectiveness of peer support for breast cancer survivors has varied substantially, and no previous study has examined patient-supporter matching. This study protocol describes a decentralized, multicenter...
Prevention of hepatitis B virus reactivation according to hepatitis B surface antigen status in patients receiving systemic chemotherapy in Japan using an electronic medical record database [0.03%]
日本电子病历数据库中系统化疗患者的乙型肝炎表面抗原状态指导的乙肝病毒再激活预防研究
Masakatsu Hattori,Kayoko Mizuno,Munenori Honda et al.
Masakatsu Hattori et al.
Background: Hepatitis B virus (HBV) reactivation is a critical complication in patients receiving systemic chemotherapy. While current guidelines recommend screening, whether appropriate preventive measures are implemente...
Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study) [0.03%]
Modified Extreme方案与Modified Tpex方案作为复发或转移性头颈部鳞癌一线治疗的多中心开放标签、随机探索性研究(温帕研究)
Motoyuki Suzuki,Akehito Kishino,Masashi Sugasawa et al.
Motoyuki Suzuki et al.
Background: The EXTREME regimen is the standard first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), but it is poorly tolerated in Asian patients. We aimed to compare ...
Effectiveness of first-line combination chemotherapy in older patients with unresectable advanced gastric cancer: a retrospective study [0.03%]
老年不可手术晚期胃癌一线联合化疗疗效的回顾性研究
Ryuya Yamamoto,Yoko M Nakao,Satomi Yoshida et al.
Ryuya Yamamoto et al.
Background: Combination therapy is the standard treatment for curatively unresectable gastric cancer; however, its effectiveness in patients aged ≥ 75 years remains unclear. This study investigated the effectiveness of c...
Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy [0.03%]
免疫检查点抑制剂联合治疗后发生完全缓解的转移性肾细胞癌患者的临床评估
Kazuhiko Yoshida,Tsunenori Kondo,Junpei Iizuka et al.
Kazuhiko Yoshida et al.
Background: Achieving a complete response (CR) with immune checkpoint inhibitor (ICI)-based combination therapy is important in metastatic renal cell carcinoma (mRCC) systemic treatment. Surgical intervention for residual...